-+ 0.00%
-+ 0.00%
-+ 0.00%

Aura Biosciences completes enrollment in Phase 3 CoMpass trial of bel-sar in early choroidal melanoma

PUBT·06/01/2026 12:01:01
Listen to the news
Aura Biosciences completes enrollment in Phase 3 CoMpass trial of bel-sar in early choroidal melanoma
  • Aura Biosciences completed enrollment of 108 patients in the Phase 3 CoMpass trial of bel-sar in early choroidal melanoma.
  • Topline results for the 15-month primary endpoint have not been presented; they are expected in the second half of 2027.
  • The trial is designed to determine whether bel-sar can work as a frontline, vision-preserving treatment versus a sham control.
  • The study is intended to support a potential regulatory filing, positioning bel-sar as a possible first approved frontline option in this setting.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aura Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606010800PRIMZONEFULLFEED9729005) on June 01, 2026, and is solely responsible for the information contained therein.